BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36779771)

  • 1. Aggressive versus indolent insulinomas: new clinicopathological insights.
    Hackeng WM; Brosens LAA; Dreijerink KMA
    Endocr Relat Cancer; 2023 May; 30(5):. PubMed ID: 36779771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative Lengthening of Telomeres and Differential Expression of Endocrine Transcription Factors Distinguish Metastatic and Non-metastatic Insulinomas.
    Hackeng WM; Schelhaas W; Morsink FHM; Heidsma CM; van Eeden S; Valk GD; Vriens MR; Heaphy CM; Nieveen van Dijkum EJM; Offerhaus GJA; Dreijerink KMA; Brosens LAA
    Endocr Pathol; 2020 Jun; 31(2):108-118. PubMed ID: 32103422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic insulinoma: exploration from clinicopathological signatures and genetic characteristics.
    Zhang J; Jiang R; Hong X; Wu H; Han X; Wu W
    Front Oncol; 2023; 13():1109330. PubMed ID: 37251916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.
    Hackeng WM; Brosens LAA; Kim JY; O'Sullivan R; Sung YN; Liu TC; Cao D; Heayn M; Brosnan-Cashman J; An S; Morsink FHM; Heidsma CM; Valk GD; Vriens MR; Nieveen van Dijkum E; Offerhaus GJA; Dreijerink KMA; Zeh H; Zureikat AH; Hogg M; Lee K; Geller D; Marsh JW; Paniccia A; Ongchin M; Pingpank JF; Bahary N; Aijazi M; Brand R; Chennat J; Das R; Fasanella KE; Khalid A; McGrath K; Sarkaria S; Singh H; Slivka A; Nalesnik M; Han X; Nikiforova MN; Lawlor RT; Mafficini A; Rusev B; Corbo V; Luchini C; Bersani S; Pea A; Cingarlini S; Landoni L; Salvia R; Milione M; Milella M; Scarpa A; Hong SM; Heaphy CM; Singhi AD
    Gut; 2022 May; 71(5):961-973. PubMed ID: 33849943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approach to the Patient: Insulinoma.
    Hofland J; Refardt JC; Feelders RA; Christ E; de Herder WW
    J Clin Endocrinol Metab; 2024 Mar; 109(4):1109-1118. PubMed ID: 37925662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
    Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
    Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical Glucagon-like Peptide-1 Receptor Expression in Human Insulinomas.
    Vesterinen T; Peltola E; Leijon H; Hannula P; Huhtala H; Mäkinen MJ; Nieminen L; Pirinen E; Rönty M; Söderström M; Jaatinen P; Arola J
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromosomal instability predicts metastatic disease in patients with insulinomas.
    Jonkers YM; Claessen SM; Perren A; Schmid S; Komminoth P; Verhofstad AA; Hofland LJ; de Krijger RR; Slootweg PJ; Ramaekers FC; Speel EJ
    Endocr Relat Cancer; 2005 Jun; 12(2):435-47. PubMed ID: 15947114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into Epigenetic Changes Related to Genetic Variants and Cells-of-Origin of Pancreatic Neuroendocrine Tumors: An Algorithm for Practical Workup.
    Ciobanu OA; Martin SC; Herlea V; Fica S
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system.
    Hong X; Qiao S; Li F; Wang W; Jiang R; Wu H; Chen H; Liu L; Peng J; Wang J; Jia C; Liang X; Dai H; Jiang J; Zhang T; Liao Q; Dai M; Cong L; Han X; Guo D; Liang Z; Li D; Zheng Z; Ye C; Li S; Zhao Y; Wu K; Wu W
    Gut; 2020 May; 69(5):877-887. PubMed ID: 31462556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.
    de Wilde RF; Heaphy CM; Maitra A; Meeker AK; Edil BH; Wolfgang CL; Ellison TA; Schulick RD; Molenaar IQ; Valk GD; Vriens MR; Borel Rinkes IH; Offerhaus GJ; Hruban RH; Matsukuma KE
    Mod Pathol; 2012 Jul; 25(7):1033-9. PubMed ID: 22575867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting recurrence in pancreatic neuroendocrine tumours: role of ARX and alternative lengthening of telomeres (ALT).
    Neyaz A; Crotty R; Rickelt S; Pankaj A; Stojanova M; Michelakos TP; Sekigami Y; Kontos F; Parrack PH; Patil DT; Heaphy CM; Ferrone CR; Deshpande V
    Histopathology; 2023 Oct; 83(4):546-558. PubMed ID: 37455385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case Report: Giant insulinoma, a very rare tumor causing hypoglycemia.
    Tarris G; Rouland A; Guillen K; Loffroy R; Lariotte AC; Rat P; Bouillet B; Andrianiaina H; Petit JM; Martin L
    Front Endocrinol (Lausanne); 2023; 14():1125772. PubMed ID: 37234805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiling in insulinomas of Men1 beta-cell mutant mice reveals early genetic and epigenetic events involved in pancreatic beta-cell tumorigenesis.
    Fontanière S; Tost J; Wierinckx A; Lachuer J; Lu J; Hussein N; Busato F; Gut I; Wang ZQ; Zhang CX
    Endocr Relat Cancer; 2006 Dec; 13(4):1223-36. PubMed ID: 17158767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-functioning neuroendocrine pancreatic tumors transforming to malignant insulinomas - four cases and review of the literature.
    Juhlin CC; Skoglund S; Juntti-Berggren L; Karlberg M; Calissendorff J
    Neuro Endocrinol Lett; 2019 Nov; 40(4):175-183. PubMed ID: 32087093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased EpCAM expression in malignant insulinoma: potential clinical implications.
    Raffel A; Eisenberger CF; Cupisti K; Schott M; Baldus SE; Hoffmann I; Aydin F; Knoefel WT; Stoecklein NH
    Eur J Endocrinol; 2010 Feb; 162(2):391-8. PubMed ID: 20097833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histologic and Molecular Profile of Pediatric Insulinomas: Evidence of a Paternal Parent-of-Origin Effect.
    Bhatti TR; Ganapathy K; Huppmann AR; Conlin L; Boodhansingh KE; MacMullen C; Becker S; Ernst LM; Adzick NS; Ruchelli ED; Ganguly A; Stanley CA
    J Clin Endocrinol Metab; 2016 Mar; 101(3):914-22. PubMed ID: 26756113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulinoma in childhood: a retrospective review of 22 patients from one referral centre.
    Melikyan M; Gubaeva D; Shadrina A; Bolmasova A; Kareva M; Tiulpakov A; Efremenkov A; Sokolov Y; Brusgaard K; Christesen HT; Andersen K; Stepanov A; Averyanova J; Makarov S; Gurevich L
    Front Endocrinol (Lausanne); 2023; 14():1127173. PubMed ID: 37152923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular parameters associated with insulinoma progression: chromosomal instability versus p53 and CK19 status.
    Jonkers YM; Claessen SM; Veltman JA; Geurts van Kessel A; Dinjens WN; Skogseid B; Ramaekers FC; Speel EJ
    Cytogenet Genome Res; 2006; 115(3-4):289-97. PubMed ID: 17124412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA copy number status is a powerful predictor of poor survival in endocrine pancreatic tumor patients.
    Jonkers YM; Claessen SM; Perren A; Schmitt AM; Hofland LJ; de Herder W; de Krijger RR; Verhofstad AA; Hermus AR; Kummer JA; Skogseid B; Volante M; Voogd AC; Ramaekers FC; Speel EJ
    Endocr Relat Cancer; 2007 Sep; 14(3):769-79. PubMed ID: 17914106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.